ANDA 202506, held by Watson Labs Inc. Sildenafil Citrate.
As of Nov 15, 2026, ANDA 202506 (Sildenafil Citrate), held by Watson Labs Inc, was first approved by FDA on Nov 25, 2020, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 25, 2020 | Original application | Approved | None posted |
| Sildenafil CitrateEQ 25MG BASE · tablet;oral | Sildenafil Citrate | Discontinued |
| Sildenafil CitrateEQ 50MG BASE · tablet;oral | Sildenafil Citrate | Discontinued |
| Sildenafil CitrateEQ 100MG BASE · tablet;oral | Sildenafil Citrate | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
